Acquired RD3 loss regulates immune surveillance in high-risk and therapy defying progressive neuroblastoma
Cancer Commun (Lond)
.
2024 Dec;44(12):1427-1430.
doi: 10.1002/cac2.12620.
Epub 2024 Oct 24.
Authors
Poorvi Subramanian
1
,
Sreenidhi Mohanvelu
1
,
Dinesh Babu Somasundaram
2
,
Sheeja Aravindan
2
,
Natarajan Aravindan
1
2
Affiliations
1
Department of Physiological Sciences, Oklahoma State University, Stillwater, Oklahoma, USA.
2
Stephenson Cancer Center, Oklahoma City, Oklahoma, USA.
PMID:
39445727
PMCID:
PMC11666958
DOI:
10.1002/cac2.12620
No abstract available
Publication types
Letter
Grants and funding
DoD CA-210339/U.S. Department of Defense
HR19-045/Oklahoma Center for the Advancement of Science and Technology
P20GM103639/NH/NIH HHS/United States
P30CA225520/National Cancer Institute Cancer Center Support Grant
R23-03/Oklahoma Tobacco Settlement Endowment Trust
P20GM103639/NH/NIH HHS/United States